Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the safety and effects of a new medicine called etavopivat in treating pediatric patients with sickle cell disease who are at increased risk for primary stroke. Participants will be grouped based on their transcranial doppler TCD ultrasound results and whether they are taking hydroxyurea, a medication already used for this condition. The study focuses on those with conditional or abnormal TCD results, with the study doctor determining the classification. This is a phase 2, open-label trial designed to assess etavopivats activity on blood flow velocities in key brain arteries. Participants will receive 400 mg of etavopivat orally once daily for a 52-week treatment period. This dose consists of two 200 mg tablets taken with water, with or without food. Participants are divided into two cohorts one receiving etavopivat alone, and another receiving etavopivat in combination with a stable dose of hydroxyurea. After the initial treatment period, there is an optional 48-week extension to further evaluate the safety of etavopivat in pediatric patients. At the studys conclusion, participants may have the option to join a separate study to continue etavopivat treatment. Throughout the study, participants will visit the clinic frequently for assessments, including transcranial doppler ultrasound measurements to track blood flow velocities at various time points. Researchers will monitor changes in the highest time-averaged maximum mean velocities TAMMV in the internal carotid and middle cerebral arteries, as well as the incidence of changes in TCD velocity categories. Safety and treatment effects will be closely observed during both the primary and optional extension periods, with total participation lasting up to 100 weeks if the extension is chosen.
Actively Recruiting
Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
This research aims to evaluate cancer treatment based on HER2 status in Nigerian women with HER2-positive breast cancer. The study focuses on assessing the safety and effectiveness of anti-HER2 therapy given before and after surgery. It specifically looks at how well the treatment works and its safety when combined with chemotherapy. Participants will receive a combination of trastuzumab and pertuzumab PHESGO along with chemotherapy. Initially, all participants get docetaxel injections for 4-6 cycles while receiving trastuzumab and pertuzumab as subcutaneous injections for 52 weeks. Depending on how their cancer responds after this phase, some will undergo surgery and continue receiving pertuzumab and trastuzumab for 36 weeks, possibly with hormone therapy such as tamoxifen, letrozole, or goserelin. Others with less favorable responses will receive trastuzumab emtansine intravenously plus standard chemotherapy. During the study, participants will have regular assessments including ultrasounds to monitor tumor response, laboratory tests, and echocardiograms to check heart function. Researchers will track outcomes like pathological complete response, adverse events, quality of life, and survival over 10 years. The study involves continuous monitoring and follow-up to evaluate treatment effects and safety throughout this period.
Actively Recruiting
Healthy Volunteer
Tuberculosis TB is a serious infectious disease caused by Mycobacterium tuberculosis, leading to millions of cases and deaths worldwide, particularly in developing countries like Nigeria. TB mainly affects the lungs and is worsened by HIV infection, making it a top cause of death globally. The trial investigates atorvastatin, a cholesterol-lowering drug, to see if it can improve TB treatment by reducing bacteria and lung damage, building on promising earlier studies that showed atorvastatin was safe and may enhance TB therapy outcomes. The trial is a phase IIC, multicenter, randomized, open-label study comparing four treatment groups three different daily doses of atorvastatin 20mg, 40mg, 60mg given for 16 weeks along with standard 6-month anti-TB therapy, and a control group receiving standard therapy alone. Patients are randomly assigned to one of these groups and followed closely for 12 months after starting treatment. The study aims to evaluate safety, the speed at which TB bacteria clear from sputum, improvement in chest X-rays, and lung function. Participants aged 12 to 65 with active pulmonary TB will undergo screening including medical history, HIV and diabetes testing, sputum cultures, blood tests, lung function, and pregnancy tests for women. During the study, sputum samples, blood tests, chest X-rays, and lung function will be monitored regularly. Researchers will track side effects and measure outcomes like TB disease-free survival and symptom improvement at 6 and 12 months. The long follow-up period allows for detailed assessment of treatment effects and safety.
Actively Recruiting
Young people living with HIV Y-PLWH often face psychological distress and depression, which negatively affect their medication adherence and disease control. This issue is especially challenging in low- and middle-income countries like Nigeria, where there are few trained mental health professionals and frequent clinic visits can cause additional costs, inconvenience, and stigma. Researchers are evaluating an interactive narrative game called Change My Story combined with Problem Solving Therapy PST compared to PST alone in a pilot randomized controlled trial among 80 Y-PLWH with depression or psychological distress. Participants will be assigned to one of two groups one group will receive PST alone delivered through a stepped-care approach with therapy sessions and follow-up based on depression scores, while the other group will receive PST plus access to the Change My Story game on their phones. The game encourages weekly play and helps address key drivers of psychological distress through interactive narratives. Participants in both groups will be monitored for depression, suicidality, and treatment response, with referrals to medical or psychiatric care if needed. During the study, participants will engage in therapy sessions, complete depression screenings, and report on their engagement, satisfaction, and feasibility of the interventions over three months. Outcomes measured include remission of depression and psychological distress, antiretroviral therapy adherence, and viral suppression at 3 and 6 months. The trial aims to assess acceptability, engagement, and barriers to implementation of the game combined with PST. The total study duration is up to 6 months with ongoing evaluation of mental health and HIV care outcomes.
Actively Recruiting
Researchers are studying the safety and drug levels of dolutegravir given twice daily in children aged 4 weeks to under 6 years who have both HIV and tuberculosis TB. The study focuses on how dolutegravir works when taken with standard and higher doses of rifampicin, a TB medicine, since current rifampicin doses may be too low for children. This research aims to better understand treatment effects and improve outcomes in this vulnerable group. Children in this study will receive HIV and TB treatments according to current care standards. For weeks 20 and 21, the dose of rifampicin will be increased to a higher level to observe how it affects dolutegravir levels and safety. Blood samples will be collected during weeks 20, 22, and 30 to measure drug concentrations and assess biomarkers related to drug processing in the body. Participants will be monitored through clinical and laboratory tests over a 48-week period. Blood samples will be taken multiple times to assess drug levels and a specific biomarker to understand drug effects better. Safety will be closely followed, especially during the higher rifampicin dose period. The main outcomes include measuring dolutegravir exposure during standard and high-dose rifampicin and monitoring for any serious adverse events by week 48.
Actively Recruiting
Tuberculosis TB is a leading cause of death among children living with HIV, but there is limited data on how new TB prevention treatments work in this group. This research evaluates the pharmacokinetics, or how drugs move through the body, of weekly rifapentine and isoniazid 3HP combined with dolutegravir in children with HIV. The study focuses on filling knowledge gaps about these short-course TB prevention regimens in vulnerable pediatric patients. Children aged 2 to 11 years receive standard HIV treatment with dolutegravir plus weekly rifapentineisoniazid for 12 weeks, following World Health Organization guidelines for latent TB infection treatment. Children under 2 years get standard dolutegravir-based HIV treatment, a single dose of weekly rifapentineisoniazid for study purposes, then daily isoniazid prophylaxis. The studys main intervention involves additional blood sampling to measure drug levels and biomarkers, with clinical and laboratory safety monitoring during the 48-week study. Participants undergo pharmacokinetic blood sampling at weeks 4, 6, and 7 to assess drug concentrations, along with biomarker testing to understand drug activity. Safety labs and clinical monitoring continue throughout the study period. Researchers will measure dolutegravir exposure during rifapentineisoniazid treatment as the primary outcome, alongside rifapentine levels and adverse events up to week 48. The study lasts approximately 48 weeks per participant.
Actively Recruiting
Medical oxygen is a vital medicine needed especially for children with conditions causing low oxygen in the blood, such as pneumonia and neonatal diseases. This research evaluates the REAL-MOXY program, which aims to strengthen oxygen systems across different countries by studying how oxygen and pulse oximetry are used in health facilities. The program addresses challenges like unequal access, healthcare worker capacity, and data management to improve oxygen availability and use. The study involves five mixed-method sub-studies conducted in six countries, focusing on children under 15 years old. These sub-studies examine baseline oxygen practices and facility readiness, map patient care pathways, observe emergency care sequences, study healthcare worker oxygen use, and gather perspectives from patients, caregivers, and staff. Interventions vary by country but broadly include strengthening oxygen policies, training workers, and improving data systems. Participants are observed and interviewed across multiple health facilities over five years to understand oxygen system functioning and barriers. Data collected include facility assessments, patient and equipment flow mapping, direct observations of care, and interviews with healthcare providers and patients. The primary outcome is the mixed-methods evaluation of oxygen use and system readiness, guiding better oxygen access strategies in diverse settings.
1-10 of 20
1